Mitsubishi tanabe , outperform   invokana nice to have a clean label yet a long way to go before gaining full confidence! - Reports Corner
Upcoming SlideShare
Loading in...5
×
 

Mitsubishi tanabe , outperform invokana nice to have a clean label yet a long way to go before gaining full confidence! - Reports Corner

on

  • 541 views

Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in ...

Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL, CV events observed in first 30 days in CANVAS study), associated genital/UTI infections, compromised efficacy in renally impaired patients and long term safety study requirements by FDA (Table 1), should be seen in conjunction with the 'clean label'.

https://www.reportscorner.com/reports/14937/MITSUBISHI-TANABE-,-Outperform---Invokana:-Nice-to-Have-A-Clean-Label,-Yet-A-Long-Way-To-Go-Before-Gaining-Full-Confidence!-/

Statistics

Views

Total Views
541
Views on SlideShare
541
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Mitsubishi tanabe , outperform   invokana nice to have a clean label yet a long way to go before gaining full confidence! - Reports Corner Mitsubishi tanabe , outperform invokana nice to have a clean label yet a long way to go before gaining full confidence! - Reports Corner Presentation Transcript

    • RCReports CornerMITSUBISHI TANABE , Outperform - Invokana: Nice to Have AClean Label, Yet A Long Way To Go Before Gaining FullConfidence!
    • DescriptionDescriptionReports Cornerwww.reportscorner.comInvokana clean label thrills many on the street rising hopes thatInvokana sales could cross $2.5b+ at peak. However we think thatCV issues (dose dependent increase in LDL, CV events observedin first 30 days in CANVAS study), associated genital/UTIinfections, compromised efficacy in renally impaired patients andlong term safety study requirements by FDA (Table 1), should beseen in conjunction with the clean label.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comInvokana clean label thrills many on the street rising hopes thatInvokana sales could cross $2.5b+ at peak. However we think thatCV issues (dose dependent increase in LDL, CV events observedin first 30 days in CANVAS study), associated genital/UTIinfections, compromised efficacy in renally impaired patients andlong term safety study requirements by FDA (Table 1), should beseen in conjunction with the clean label. These issues will limitthe initial uptake of Invokana to a small segment of diabeticpatients - we think patients moving to triple OAD, on GLP-1 orInsulin (due to insufficient control from existing therapies, andescalating disease) are the broader target base of Invokana.Within this broader patient pool, ~40% patients with renal risks,>30% obese patients with co-morbid conditions and CV risks, andfemales at high UTI infection risk need to be restricted further –this leaves a merely ~263k (or ~2.1% of total OAD patients)patients in the US for SGLT-2 inhibitors.
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comTaking All Factors into Account, We arrive the Following TargetPatient Base for Invokana (Table 4, 5- Invokana Market Model):……………………….We expect the market share to split between Invokana:Empagliflozin: Dapagliflozin by ~55:35:10 respectively asBased on the available data comparision of Empagliflozin vs.Invokana, its efficacy looks better than Empagliflozin. While onsafety front, based on PhIIb data empagliflozin reported lessgenital mycotic infections and equivalent UTI infection toInvokana when indirectly compared.…………………………What to watch next in the SGLT2 class? ............
    • Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comKey Tables:Invokana- Post Marketing Study Required by FDASGLT2 inhibitors: Efficacy ComparisionSGLT2 inhibitors: Safety ComparisionInvokana- Assumption/Target Patient PopulationInvokana – Market ModelSGLT2 Pipeline (Japan and Global Status)
    • Table of ContentsTable of ContentsReports Cornerwww.reportscorner.comInvokana- Post Marketing Study Required by FDASGLT2 inhibitors: Efficacy ComparisionSGLT2 inhibitors: Safety ComparisionInvokana- Assumption/Target Patient PopulationInvokana – Market ModelSGLT2 Pipeline (Japan and Global Status)
    • For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our websitehttps://www.reportscorner.com/reports/14937/MITSUBISHI-TANABE-,-Outperform---Invokana:-Nice-to-Have-A-Clean-Label,-Yet-A-Long-Way-To-Go-Before-Gaining-Full-Confidence!-/
    • Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: contact@reportscorner.com